Flibanserin and its discontents
- 266 Downloads
In August 2015, flibanserin (brand name Addyi) was approved by the Food and Drug Administration (FDA) for treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. This article summarizes and promotes discussion regarding the numerous controversies that have enclosed flibanserin since the very beginning. This includes questions related to flibanserin’s safety and efficacy and the validity of the clinical trials. Also included are philosophical considerations surrounding the diagnosis of hypoactive sexual desire disorder and pharmacological treatment of low libido. Based on the review of literature, authors judge flibanserin to be modestly effective and reasonably safe, and discuss the differences in philosophical perspectives with less definitive answers.
KeywordsFlibanserin Hypoactive sexual desire disorder Female sexuality Women’s mental health Ethics
The authors would like to thank Erum Ahmad and John DeMott for their helpful thoughts and suggestions.
AA conceived of the subject and conceptualized the outline of the paper. The literature search, writing, and editing were done by all three authors collaboratively.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflicts of interest.
- Advisory Committee Meeting Document (2015) Flibanserin for the treatment of hypoactive sexual desire disorder in premenopausal women. Bone, Reproductive and Urologic Drugs Advisory Committee Meeting, Drug Safety and Risk Management Advisory Committee. p. i-xvi. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/drugsafetyandriskmanagementadvisorycommittee/ucm449090.pdf. Accessed 6 Mar 2016
- BBC (2015, Aug 19) ‘Female Viagra’—a closer look at flibanserin. http://www.bbc.com/news/health-33984472. Accessed 6 Mar 2016
- Clayton AH, DeRogatis LR, Rosen RC, Pyke R (2012) Intended or unintended consequences? The likely implications of raising the bar for sexual dysfunction diagnosis in the proposed DSM‐V revisions: 1. For women with incomplete loss of desire or sexual receptivity. J Sex Med 9:2027–2039. doi: 10.1111/j.1743-6109.2012.02850.x CrossRefPubMedGoogle Scholar
- Derogatis LR, Komer L, Katz M, Moreau M, Kimura T, Garcia M Jr, Wunderlich G, Pyke R, VIOLET Trial Investigators (2012) Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the VIOLET Study. J Sex Med 9:1074–1085. doi: 10.1111/j.1743-6109.2011.02626.x CrossRefPubMedGoogle Scholar
- FDA (2015) ADDYI (flibanserin). FDA product labelling. p 3. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022526lbl.pdf. Accessed 26 Mar 2016
- FDA (2016) CIALIS (tadalafil). FDA product labelling. p 17. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021368s027lbl.pdf. Accessed 4 Nov 2016
- Goldschmidt D (2015, August 18) ‘Female Viagra’ gets FDA approval. CNN. http://www.cnn.com/2015/08/18/health/female-viagra-fda-approval/. Accessed 6 Mar 2016
- Jaspers L, Feys F, Bramer WM, Franco OH, Leusink P, Laan ET (2016) Efficacy and safety of flibanserin for the treatment of hypoactive sexual desire disorder in women: a systematic review and meta-analysis. JAMA Intern Med 176:453–462. doi: 10.1001/jamainternmed.2015.8565 CrossRefPubMedGoogle Scholar
- Nagoski E (2015) Nothing is wrong with your sex drive. The New York Times. http://www.nytimes.com/2015/02/27/opinion/nothing-is-wrong-with-your-sex-drive.html. Accessed 2 Feb 2016
- Thorp J, Simon J, Dattani D, Taylor L, Kimura T, Garcia M Jr, Lesko L, Pyke R, DAISY Trial Investigators (2012) Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study. J Sex Med 9:793–804. doi: 10.1111/j.1743-6109.2011.02595.x CrossRefPubMedGoogle Scholar
- US Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER) (2000). Draft guidance for industry: female sexual dysfunction: clinical development of drug products for treatment. http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4082B1_02_C-FDA-Appendix-1.pdf. Accessed 6 Mar 2016
- Yuko E (2015) The FDA, finances and feminism: why the third time was the charm for so-called ‘female Viagra’. The Huffington Post. 2015, August 24. http://www.huffingtonpost.com/elizabeth-yuko/the-fda-finances-feminism_b_8021828.html. Accessed 6 Mar 2016